Efficacy of Pilocarpine As a Secretagogue Versus Artificial Tears for the Treatment of Dry Eye

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06752278

Enrollment

Registered

2024-12-30

Start date

2024-10-01

Completion date

2024-12-20

Last updated

2024-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye Disease (DED)

Brief summary

Management approaches for dry eye disease (DED) typically start with low-risk, easily accessible, patient-applied therapies like artificial tears for early-stage disease. As the condition worsens, treatment progresses to more advanced therapies for severe forms of DED. This study aims to compare the effectiveness and safety of pilocarpine as a secretagogue versus artificial tears in the treatment of dry eye disease. Our goal is to provide reliable, high-quality evidence regarding the efficacy of secretagogues, thereby contributing to the development of recommendations that aid clinicians in their decision-making process

Interventions

DRUGPilocarpine

Pilocarpine is a muscarinic agonist

DRUGartificial tears

artificial tears used for the treatment of Dry eye

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients diagnosed with DED

Exclusion criteria

* Previous Occular surgery. * Refuse to particupate. * Patients with sjogren syndrome

Design outcomes

Primary

Measure	Time frame
Ocular Surface Disease Index	At the baseline and after 6 weeks
tear film break-up time	At the baseline and after 6 weeks

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026